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Summary This eChapter has an introduction to pharmacology and drug nomenclature 
followed by a detailed discussion of routes of administration starting with oral administration 
(with absorption from the gastrointestinal tract, and first pass liver metabolism. This is 
followed by a discussion of rectal, sublingual and injection routes of administration 
(intravenous, intra-arterial, subcutaneous, intramuscular, intrathecal and epidural).  Then the 
topical, pulmonary and intraosseus routes of administration are considered. 
1.1 Introduction to Pharmacology 
Pharmacology is the study of all aspects relating to drugs or medicines.  Some of us, use the 
term ‘drugs’ to cover medicines (prescription and non-prescription) and drugs of abuse (legal 
and illicit), and this is how I am going to use ‘drugs’ in this Unit.  The popular press often 
uses the term ‘drugs’ to mean drugs of abuse, and this can be confusing.  Some medicines can 
also be drugs of abuse, which further complicates the issue.  For example, morphine is both a 
potent pain reliever and a drug of abuse. 
There are a huge number of drugs available in Australia.  Currently there are 27,000 drugs on 
the Australian Register of Therapeutic Goods (ARTG) and, of these, 3,500 are registered as 
prescription only. 
Pharmacology can be divided into two parts; pharmacokinetics and pharmacodynamics.   
Pharmacokinetics is ‘What the body does to the drug’.  After administration, the drugs 
usually has to be absorbed into the body, may be distributed around the body, and/or 
metabolised, and will eventually be excreted/eliminated.  Absorption (A), distribution (D), 
metabolism (M) and excretion/elimination (E), sometimes referred to as ADME, are all 
pharmacokinetic processes and they may be altered in disease states.  This is important, as we 
most commonly use drugs in disease states. 
Pharmacodynamics is ‘What the drug does to the body’.  When we administer a drug to a 
person, we hope that the drug will have a beneficial effect.  In order to do so, the drug will 
have to cause an alteration in a physiological, biochemical or pathological process.  This 
alteration is called the mechanism of action or pharmacodynamics of the drug.  It is the 
molecular mechanism of action of the drug, and the actions of the drug in the human body 
that follow from this mechanism of action. 
Pharmacokinetics and pharmacodynamics are related, as shown in Figure 1.1.   
.  
Figure 1.1 Relationship between pharmacokinetics and pharmacodynamics (Copyright QUT, 
Sheila Doggrell) 
Pharmacokinetics includes ADME; Absorption, Distribution, Metabolism and Elimination.  
After administration, drugs undergo absorption into the systemic circulation, this is the 
circulation that takes blood to most parts of the body, and will take the absorbed drugs with 
it.  Drugs can be further distributed into tissues or fat, and may also be released back into the 
circulation from the tissues and fat.  Drugs are often targeted to have actions at specific sites, 
and when the drug reaches this site, the process of pharmacodynamics starts.  
Pharmacodynamics is a change in the body system – hopefully for a beneficial effect.  After 
having an effect, the drug often returns to the circulation, where it will be taken in the 
circulation to its site of metabolism, which is commonly the liver.  After metabolism drugs 
are removed from the body by excretion, commonly from the kidney.  Some drugs are not 
metabolised but are directly eliminated via the kidneys. 
In addition to pharmacokinetics and pharmacodynamics, there are some other 
pharmac…..terms used in pharmacology.  The first is pharmaceutics, which has some 
overlap with pharmacokinetics.  Pharmaceutics is designing formulations of drugs suitable 
for administration to people.  Pharmacogenetics is the genetic basis for variation in drug 
response.  This variation can have a basis in pharmacokinetics or pharmacodynamics, and we 
will discuss examples of these later.  Pharmacovigilance is the detection, assessment, 
understanding, and prevention of adverse drug effects and adverse drug interactions.  Some 
of these adverse effects and adverse drug interactions are at the level of pharmacokinetics and 
some at the level of pharmacodynamics.  Examples of pharmacovigilance will be discussed 
later.   
1.2 Drug Nomenclature 
An important issue to learn about at the start of a Unit in pharmacology is drug 
nomenclature.   When I tell people that I am a pharmacologist, people often respond by 
saying “I’m taking Tenormin for my hypertension – do you know anything about this drug?”  
Tenormin is a tradename, and pharmacologists do not use trade names.  So, I usually reply 
that “Tenormin is a tradename, and I can’t tell you anything about it unless you give me the 
real name of the drug”.  Tenormin is actually atenolol, a β-blocker commonly used in the 
treatment of hypertension, and I know a lot about atenolol. 
Each drug actually has 3 names.  The first is the chemical name, and is the name used by 
chemists to describe the chemical structure.  The second name is the generic, and this is the 
one used by pharmacologists.  The generic name is also known as the non-proprietary name 
to distinguish it from the proprietary or trademark name.  The trade name is used by the 
pharmaceutical companies.  To give an example: the chemical name for diazepam is 7-
chloro-1,3-dihydro-1-methyl-5-phenyl-2H-,1,4-benzodiazepin-2-on, and from this name, a 
chemist could draw the structure.  The generic name is diazepam, which is a commonly used 
sedative.  The third name is the proprietary or tradename.  Each company can have a different 
tradename (brand name) for the same drug, the best known proprietary or tradename for 
diazepam is Valium (from the pharmaceutical company Roche), but other proprietary names 
for diazepam include Valpam (Arrow), Antenex (Alphapharm) and Ducene (Sauter).  Thus, 
there are at least 4 different trade names for the same drug.  Pharmaceutical companies 
probably like the use of their tradename, as this gives them some free advertising.  However, 
it is more correct (and less confusing) to use generic names.  Generic names are used 
throughout this Unit and eBook. 
 
1.3 Introduction to drug administration and absorption of drugs 
The first step in pharmacokinetics is the administration and absorption of drugs.  The 
chemical structure and nature of a drug may determine which route of administration can be 
used for? a drug.  Drug absorption depends on the route of administration.  When a drug is 
administered into the mouth (orally), absorption will be from the gastrointestinal tract.  
However, if a drug is administered into a vein (intravenously), absorption will be from the 
circulation. 
1.4 Routes of drug administration 
The routes of drug administration are described as enteral, which means into the 
gastrointestinal tract, or parenteral (not into the gastrointestinal tract).  Routes that are 
enteral (into the gastrointestinal tract) are oral and rectal.  Routes that are parenteral include 
sublingual (under the tongue) and injection, which can be to a variety of sites e.g. into the 
vein (intravenous), into the muscle (intramuscular), under the skin (subcutaneous).  Other 
parenteral routes include topical, which is to a body surface, such as the skin, nose, eyes etc. 
and pulmonary, which is delivery to the lungs.  These routes of drug administration are 
considered in sequence.  The route of administration used for a drug may also depend on 
whether a systemic (around the body) effect is required.  Local administration is a way of 
trying to limit the effects of a drug to a local area.  
1.5 Oral administration, absorption from gastrointestinal tract, and first pass 
liver metabolism 
The oral route of administration is the most convenient: subjects prefer to take an oral 
preparation rather than have an injection, or rectal administration.  Oral administration is also 
the safest.  For instance, we have more time to reverse the effects of a drug administered 
orally than when it is administered directly into a vein.  Oral is the most commonly used 
route of administration.  Oral administration usually gives systemic effects (around the body) 
rather than local effects of drugs.  Thus, after oral administration, a drug ends up in the 
systemic circulation being widely distributed to tissues and organs, with the possibility of 
having a widespread effect.  
A disadvantage of oral administration can be the slow onset of action, as the drug has to be 
absorbed and taken to its required site of action before it can start to have an effect.  In an 
emergency, drugs that are active after oral administration, may be given intravenously to 
speed up their onset of action.  If the patient is vomiting, the drug may never reach the 
intestine to be absorbed.  Thus, when the patient is vomiting, oral is not an appropriate route 
of drug administration.  
Oral preparations can take several forms.  Tablets are compressed powder, often with starch 
added to swell when in contact with fluids, to aid dissolution (breakdown of the tablet).  
Capsules contain a shell of gelatine, which is a tasteless natural substance.  Hard gelatine 
capsules contain the drug as solid, whereas soft gelatine capsules contain drug as an oily 
liquid.  Capsules are often preferred to tablets as they disguise the taste.  For instance, the 
antibiotic amoxycillin is given in capsule form to prevent its bad taste upsetting the subject.  
Children often have problems swallowing tablets or capsules.  If swallowing is a problem, 
oral liquid preparations can be used. 
The gastrointestinal tract is designed to handle food and fluids not drugs.  Drugs piggyback 
on the physiological processes to handle food.  Also, the physiological processes that 
normally impact on food and fluids, can affect drug delivery.  For instance, the digestive 
enzymes that breakdown proteins in the diet, can also breakdown some peptide drugs e.g. 
insulin.  Thus, when insulin is being used to treat diabetes, it is not administered orally.  The 
absorption of some drugs is inhibited by forming complexes with components of the diet e.g. 
the tetracycline antibiotics form non-absorbable complexes with calcium (dairy products).  
Some drugs irritate the lining of the gastrointestinal tract to cause emesis (vomiting), and 
such drugs cannot be used orally e.g. some of the cytotoxic (cell killing) anti-cancer drugs. 
The processes that need to happen to get drug delivery from the gut into the circulation are 
given in Figure 1.2.  Firstly, the drug has to be released from the dosage form (tablet or 
capsule).  Secondly, the drug has to separate and/or dissolve; this is called drug dissolution.  
After dissolution most drugs are absorbed by simple diffusion, although a few drugs are 
transported by physiological processes.    
   
Figure 1.2 Processes to get drug delivery from gut (Copyright QUT, Sheila Doggrell) 
The body has many membrane transporters.  These are like being transported by a bus; 
they pick up drugs and take them to their destination across membranes.  For instance, after 
the proteins have been broken down to amino acids, the amino acids are absorbed by active 
transport across the gut membrane.  Drugs with similar structures to the natural substrates 
(substances) for these transporters can use these transporters.  For instance, thyroxine, which 
is commonly used in the treatment of hypothyroidism, uses the physiological transporter for 
amino acid absorption.  Another example is the drug L-dopa, which is used in the treatment 
of Parkinson’s disease.  L-dopa is a naturally occurring compound, and has its own 
transporter. 
The most common method for drug absorption is diffusion.  As cell membranes are lipid, to 
diffuse through the lipid cell membranes, drugs must be lipid soluble (lipophilic).  ‘Philic’ 
means likes, whereas ‘phobic’ means does not like.     Drugs that are not water soluble 
(hydrophobic) are often lipophilic, and absorbed by diffusion.  In contrast, water soluble 
drugs (hydrophilic), which are not lipid soluble (lipophobic drugs; e.g. curare), are not well 
absorbed after oral administration.   
The case of curare tells us a lot about routes of drug administration.  Curare was used on the 
tips of the arrows of South Americans to kill animals.  Once the curare was injected into the 
animal, it became paralysed.  However, when the South Americans ate the curare-injected 
animals, they were not paralysed.  This is because curare is a strong base and not absorbed 
from the gastrointestinal tract, so has no effect after oral administration.  However, it is 
absorbed after intramuscular injection to give its muscle relaxant effect.  Curare is still used 
today to cause muscle relaxation during operations.  In addition to strong bases, strong acids 
are poorly absorbed after oral administration, and have to be given by another route. 
Strong acids and strong bases (e.g. curare) are not absorbed.  Thus, drugs are usually 
designed to be weak acids (e.g. aspirin) or weak bases (e.g. morphine), as these are more 
lipid soluble and readily diffuse through the gastrointestinal cells membranes.  Weak acids 
are lipophilic at low pH (which occurs in the stomach) and are capable of being absorbed 
from the stomach.  In contrast, weak bases are lipophilic at high pH (in the intestine), and are 
absorbed from the intestine. 
The stomach is acidic, with a pH of 1-3, compared with the small intestine, which has a pH in 
the range 5-8.  Acidity is increased at night, and this may increase the absorption of some 
drugs.  In contrast, antacids decrease the acid in the stomach, and can inhibit the absorption 
of some drugs.  As the acidity in the stomach leads to the association of weak acids, some of 
these are absorbed from the stomach.  However, the stomach is not designed for absorption, 
and most absorption occurs in the small intestine, which is designed for absorption with villi 
(projections) and microvilli giving a large surface area. 
Drugs will reach the small intestine more rapidly, if administered with water to a patient, 
whose stomach is empty of food. If a drug is absorbed lower down the gut, the volume of 
gastric contents will determine the delay before absorption starts.  Gastric contents are not the 
only determinant of rate of gastric emptying and, hence, drug absorption in the intestine.  
Gastric emptying rate is slowed by diet, especially a diet containing fatty foods or a high bulk 
diet.  Diseases of gastrointestinal tract, such as gastric ulcers or pyloric stenosis, can slow 
gastric emptying.  Gastric emptying is also slowed during pregnancy.  Certain drugs (e.g. 
anti-muscarinics) and alcohol also slow gastric emptying.  Indeed, one of the uses of 
antimuscarinics is to slow gastric emptying in dysentery.  With slow gastric emptying, there 
is more time for the breakdown of drugs by the enzymes and/or acid in the stomach, and this 
means the subsequent levels in the blood may be lower. 
Gastric emptying rate is promoted by hunger, anxiety and certain drugs (e.g. 
metoclopramide).  Increased gastric emptying may promote the absorption of any drug, and 
lead to increased blood levels.  Metoclopramide is not used to promote gastric emptying but 
as an anti-emetic (prevention of nausea and vomiting).  During this use of metoclopramide, 
there may be higher blood levels of other drugs being used at the same time. 
The small intestine is the primary site of drug absorption.  The longer the drug remains in the 
small intestine (residence time), the greater the absorption of the drug from the intestine.  
However, some drugs are metabolised and inactivated by the intestinal mucosa e.g. 
progesterone, which means they are not very effective after oral administration.  Thus, orally 
active progesterone-like drugs, designed to be active after oral administration, are part of the 
oral contraceptive, rather than progesterone itself.   
Prodrugs are compounds that are metabolised to active drugs in the body.   Some prodrugs 
rely on degradation in the intestine to release the active drug.  For instance, erythromycin 
stearate is metabolised to provide the antibiotic erythromycin. 
Drugs may have a short action if their dissolution and absorption in the gastrointestinal tract 
is too quick, or metabolism is too quick.  This may mean that a drug has to be taken often, 
say every 2 or 3 hours.  People are not very good at remembering to take drugs every 2 or 3 
hours, especially during the night, and with such regimens, people miss doses; their 
adherence to the dosage regimen is low.  For this reason, it is best to formulate drugs so that 
they only need to be taken once or twice a day. To achieve this controlled/slow (sustained) 
release preparations have been developed.  These have a slowed rate of dissolution in the 
gastrointestinal tract allowing them to be used less frequently and/or allowing the 
maintenance of a therapeutic effect overnight.  For instance, the use of nifedipine in the 
treatment of hypertension was initially not very effective as nifedipine is rapidly metabolised, 
and therefore has to be taken frequently, which patients find difficult to adhere to. With 
nifedipine SR, there is a slower dissolution of the tablet, and prolonged delivery, which 
allows nifedipine SR to be used twice a day, so nifedipine SR allows a more effective control 
of blood pressure.   
Some drugs are ineffective when administered by the oral route as they are destroyed by the 
acid in the stomach e.g. erythromycin.  Enteric-coated preparations are designed to 
prevent destruction by acid in the stomach, and this allows some of the drug, which would 
otherwise be destroyed by acid, to be effective after oral administration.  The antibiotic 
erythromycin can be used in an enteric-coated preparation. 
An important term that is often used in association with the use of medicines is 
bioavailability.  Bioavailability is the fraction of an ingested dose of a drug that gains access 
to the systemic circulation.  To reach the circulation (see Figure 1.3), drugs must penetrate 
the intestinal mucosa and avoid metabolism by the intestinal and liver enzymes.  Drugs that 
reach the blood vessels of the gastrointestinal tract are carried in the blood supply directly to 
the liver by the portal vein.  The liver is a major source of enzymes, and these enzymes are 
involved in the biochemical processes in the body.  While, none of these enzymes have drugs 
as their natural substrates, they do metabolise drugs.  Indeed, many drugs are inactivated by 
metabolism.  After oral administration, drugs cannot avoid being taken to the liver.    
Metabolism after absorption from the gut is known as First Pass Metabolism. If drugs 
undergo extensive first pass metabolism after oral administration, they are often 
administered by another route to avoid this inactivation e.g. sublingual, rectal. 
  
Figure 1.3 First pass metabolism (Copyright QUT University, Sheila Doggrell) 
Whether drugs are administered orally or by other routes, they often end up in blood vessels, 
and, to reach their target site, have to then be absorbed from blood vessels.   This occurs 
predominantly by diffusion.  Cardiovascular disease can lead to low perfusion of tissues (e.g. 
in heart failure, there is low perfusion of tissues) and this can slow the absorption of drugs.  
Conversely, exercise increases blood flow, and will increase the absorption of drugs from the 
blood vessels in skeletal muscle. 
In addition to oral administration, routes of drug administration include sublingual, rectal, 
injection, topical, and pulmonary.  Each of these routes has both advantages and 
disadvantages when compared to oral administration. 
1.6 Sublingual 
Extensive first pass liver metabolism makes it difficult to administer some drugs by the oral 
route.  Sublingual (under the tough) administration can be used to avoid first pass liver 
metabolism.  Drugs that are absorbed via the oral mucosa drain into the superior venae cavae 
to the heart and systemic circulation; they are not transported directly to the liver, and thus do 
not undergo first pass liver metabolism.  Once in the systemic circulation, only part of the 
drug will pass through the liver with each circulation - the rest will go through other organs 
or tissues, which may not metabolise the drug to destroy it: Figure 1.4. 
 
Figure 1.4 Sublingual drug administration (Copyright QUT University, Sheila Doggrell) 
The sublingual route of administration increases the bioavailability of drugs that are 
extensively metabolised by the liver.  The best known example of a drug that is used 
sublingually to avoid first pass liver metabolism is glyceryl trinitrate (nitroglycerin).  Oral 
nitroglycerin is ineffective as it is extensively metabolised by the liver, and little enters the 
circulation if taken orally.  In an attack of angina, nitroglycerin administered sublingually 
does get into the circulation, and rapidly provides relief from the attack of angina.   
1.7 Rectal 
The rectum is at the end of the large intestine, and is about 15-20 cm long.  Drugs are 
specially formulated for rectal administration, and the Solid Drug Formulations for Rectal 
Use are known as suppositories. 
Rectal administration avoids first pass liver metabolism.  This is because, after insertion into 
the lower part of the rectum, absorption is into rectal veins and then into the general 
circulation.  As the absorption is not into the portal vein, this avoids first pass metabolism.  
Another advantage of rectal administration is that the rectum has little enzymatic activity, and 
this route avoids upper gastro-intestinal acids and enzymes, which destroy many drugs.  
Rectal administration may be useful in the presence of upper gastrointestinal disease, which 
affects the absorption of the drug given via oral administration.  
Rectal administration can be useful when oral administration is not possible.  For instance, in 
nausea and vomiting, or in subjects who have difficulty in swallowing, oral administration is 
not possible.  Post-operative vomiting prevents oral administration, but drugs can be 
administered rectally to reach the circulation to be effective.  In children in status epilepticus, 
it is not possible to get the child to swallow, but rectal diazepam can be used to control the 
epilepsy.  The major disadvantage of rectal administration is that it is not popular with 
people.  
In addition to being used to achieve systemic effects, the rectal route can also be used to give 
a local effect.  For example, suppositories can be used in the treatment of haemorrhoids. 
Suppositories and enemas are different.  Enemas contain hypertonic solutions that draw 
water to them to produce a laxative effect, and are used in subjects with constipation. 
1.8 Injection 
There are mainly sites that drugs can be injected into, and the absorption will be different 
from each of these sites.  The sites include intravenous (into the vein), intra-arterial (into 
the artery), intradermal (into the dermis layer of skin), subcutaneous (under the dermis, in 
the subcutaneous tissue), intramuscular (into the muscle), intrathecal (into the cerebral 
spinal fluid), and epidural (into the epidural). 
1.8.1 Intravenous 
Injection into a vein (intravenous) relies on the skill of finding a vein, getting a needle into 
the vein, and keeping the vein open during the injection.  This is a skill that relies on practice 
at the patient’s expense!  One of the major advantages of the intravenous (i.v.) route is that it 
gives more immediacy and accuracy than other routes.  Immediacy may be required in an 
emergency situation.  Thus, when a subject has intense pain, quick pain relief is required.  
Morphine is a potent analgesic (pain reliever).  For quick pain relief, morphine is 
administered intravenously, and pain relief occurs in 10-15 minutes, whereas if morphine is 
administered orally, to takes 30 minutes to cause pain relief. 
After oral administration, in addition to the time lag for absorption, there may be a reduction 
in drug activity by liver metabolism, which gives a range of bioavailability, which is specific 
for each drug.  In contrast, intravenous administration avoids first pass liver metabolism, 
allows for a rapid effect, and the bioavailability is 100%.  Because of the greater 
bioavailability after intravenous administration, a lower dose may be required after 
intravenous administration than oral administration. For instance, when the pain killer 
pethidine is administered orally, the dose is 100 mg, and there is extensive first pass liver 
metabolism.  When pethidine is administered intravenously, there is no first pass metabolism, 
and the dose is 25 mg. 
The intravenous route of administration can be used for drugs that are not active after oral 
administration e.g. ionised drugs, peptides.  The intravenous route of administration can often 
be used for drugs that irritate the intestinal mucosa, as blood vessel walls are quite 
insensitive.  Many of the cytotoxic (cell killing) anti-cancer drugs irritate the intestinal 
mucosa but not the blood vessels walls, and are given intravenously 
One disadvantage of the intravenous route is that it is not suitable for all drugs.  Drugs in oily 
vehicles or drugs that precipitate blood constituents or haemolyse red blood cells cannot be 
used intravenously.  Another disadvantage of the intravenous route is that, with oral 
administration of the wrong drug or the wrong dose of a drug, there is an opportunity to 
remove the drug during absorption, and before it reaches the circulation, but this is not 
possible after intravenously administration.  Thus, it is a disadvantage that the actions of an 
intravenously administered drug are often not easily reversed. 
1.8.2 Intra-arterial 
The main disadvantage of intra-arterial injection (injection into an artery) is that it requires 
great care, and should only be done by experts.  If you get it wrong, there will be blood 
everywhere!  Intra-arterial (i.a.) injections are used to localise effects of a drug to a particular 
tissue or organ e.g. in the treatment of renal tumours or head/neck cancers, drugs can be 
injected into the renal artery or carotid artery, respectively.  After intra-arterial 
administration, the highest concentrations are localised and have their maximum effect 
locally.  As the drug moves away from its site of injection, it is diluted in the circulation, and 
this reduces the toxicity of the drug.  Another advantage of intra-arterial injection to the site 
of action is that it avoids first pass liver and lung metabolism. 
1.8.3 Subcutaneous 
Subcutaneous is injection of a drug under the skin.  An advantage of subcutaneous (s.c.) 
administration is that it avoids first pass liver metabolism, as the drug is released into the 
circulation, rather than specifically into the portal vein.  From the subcutaneous area, 
absorption is often by diffusion.  The drug is administered in a depot under the skin with 
absorption into plasma, and then to the circulation often sufficiently constant and slow to 
provide a sustained effect.  Thus, subcutaneous administration can provide a slow release 
preparation for ongoing effects.  Also, the rate of absorption after subcutaneous 
administration can be varied.  For instance, in diabetics, soluble insulin with rapid absorption 
can be injected subcutaneously to mimic the rapid rise in blood insulin observed with a meal.  
Whereas an insoluble suspension of insulin can be used for the slow absorption required to 
give the low constant fasting level of insulin. 
The area affected by the subcutaneous administration of a drug can be limited by the injection 
of a vasoconstrictor (e.g. adrenaline) with the drug.  The localised vasoconstriction response 
to adrenaline limits the transport of the drug away from the site of injection in the circulation. 
This method is used with local anaesthetics to keep the effect of the anaesthetic confined to a 
local area.  Without a vasoconstrictor, the local anaesthetic and the anaesthetic effects spread 
from the site of injection, and are no longer local. 
1.8.4 Intramuscular 
Intramuscular is injection into the muscle.   An advantage of intramuscular (i.m.) 
administration is that it avoids first pass liver metabolism, and it may be suitable for drugs 
that undergo extensive first pass liver metabolism.  The intramuscular route is often suitable 
for drugs that are mucosal irritants or drugs that are irritants after subcutaneous injection. 
Drugs in aqueous solution are absorbed quite rapidly from muscle, but the rate of absorption 
will depend on the rate of blood flow at the injection site.  If the blood flow is high, the rate 
of absorption will also be high.  The rate of absorption of an aqueous solution is greater from 
the deltoid (shoulder muscle) or vastus lateralis (above the knee muscle) than from the 
gluteus maximus (butt muscle).  Absorption from gluteus maximus is particularly slow in 
females who have more subcutaneous fat in this area than males, because fat slows the 
absorption.  Gardasil, the vaccine designed to prevent most cases of cervical cancer, is 
injected into the deltroid for quick absorption.   
Blood flow to the legs is increased during jogging.  If insulin is injected into the leg, rather 
that into the arm or abdominal wall, as recommended, it is absorbed quickly during jogging.  
With higher levels of insulin than expected, there is an increased take up of glucose into the 
tissues, which can cause an unwanted major drop in blood glucose leading to an episode of 
hypoglycaemia. 
1.8.5 Intrathecal 
Intrathecal is injection into the cerebral spinal fluid.  This is a method for direct delivery of a 
drug to the central nervous system.  Intrathecal is used with local anaesthetics to give 
spinal/regional anaesthesia, often prior to perform operations on low limbs.   
The opioid µ-receptors that mediate pain are in the spinal cord.  Drugs that are administered 
to the cerebral spinal fluid are being delivered to this site of pain mediation.  Thus, the 
intrathecal route of administration can be used with the opioid antagonist morphine to give 
good pain relief. 
1.8.6 Epidural 
An epidural is an injection into the epidural, which is the area above the dura mater, the layer 
before the cerebral spinal fluid.  The best known example of epidural injections is when used 
with local anaesthetics during childbirth to prevent the pain associated with childbirth. 
1.9 Topical 
Topical administration is to the surface, and is used to give local effects.  Topical 
administration avoids first pass metabolism.  However, drugs that are absorbed into the 
circulation after local administration may then have systemic effects.   
The topical surface can be skin or mucous membranes, and these have different properties.  
Mucous membranes used for drug administration include those of the conjunctiva (eye), 
nasopharynx (nose), oropharynx (throat), vagina, urethra, and urinary bladder.  Absorption 
from these mucous membranes occurs readily.  Topical administration to the skin and 
selected mucous membranes are discussed below. 
1.9.1 Skin 
Topical administration of drugs to the skin usually uses patches or ointments, which are 
applied to the skin.  The outer layer of the skin (the epidermis) is a lipid barrier, and aqueous 
solutions will only be absorbed slowly.  If necessary, absorption can be enhanced by 
suspending the drug in an oily substance and rubbing the resulting preparation into the skin.  
The epidermis is the main determinant of the rate of absorption from the skin, as the inner 
layer of the skin (the dermis) is freely permeable.  Avoidance of first pass liver metabolism is 
a major advantage with administration.  Thus, drugs that undergo extensive first pass liver 
metabolism can be used topically.  For instance, the nitrates can be given in patches that 
provide long term release and long term prevention of angina.  The nitrates have their effect 
on blood vessels, and thus require absorption into the systemic circulation to be effective. 
However, topical administration can be also be used to produce local effects and avoid 
systemic effects/side effect, when this is required.  The anti-inflammatory glucocorticoids 
can have severe adverse effects if they get into the blood stream.  However, they can be used 
safely in skin diseases with local application.  Topical administration to the skin provides the 
highest concentrations of glucocorticoids, and the majority of their effects at the required site 
(the skin).  Only low concentrations of the glucocorticoids will enter the systemic circulation 
with the potential to cause adverse effects. 
Controlled-release preparations for topical administration to the skin are increasing being 
used to give a long term steady state level of drug.  For instance, nicotine patches are 
controlled-release preparations that help to reduce cravings in smoking cessation.  Another 
example is the scopolamine patche, which is a slow release preparations to prevent motion 
sickness. 
1.9.2 Nasal mucosa 
The nasal mucosa is highly porous and permeable to drugs.  The nasal mucosa is highly 
vascularised.  The nasal mucosa also has a relatively large surface area as a result of 
microvilli on the epithelial cells, and this aids absorption from the nasal mucosa.  One 
disadvantage to the nasal route is that the drug may be rapidly removed by a runny nose.  
Thus, it is an unreliable route of administration in subjects with a cold or hayfever. 
Occasionally peptide drugs are given nasally for systemic effects.  This is because the nasal 
route avoids gut digestion by gastro-intestinal enzymes and first pass metabolism.  The 
peptide calcitonin is administered nasally when it used for its effects in preventing further 
bone loss in the treatment of osteoporosis.  However, most of the drugs that are commonly 
administered intranasally are those with effects on the nose.  For example, decongestants are 
administered to the nose, when it is congested in a cold. 
1.9.3 Eye  
When a drug is a liquid/drop form, it is placed on the conjunctiva, and the released drug 
dissolves in the tears, and following blinking, is distributed to the site of absorption, the 
cornea.  Local effects usually require absorption of the drug through the cornea.  Although 
eye drops are used for their local effects, absorption can lead to systemic effects as the drug is 
drained from the eye through the nasolacrimal canal.  As this drainage is not subject to first 
pass liver metabolism, it can lead to systemic side effects.  Absorption may be increased by 
corneal infection or trauma, and dosage and care is needed in these conditions.  An example 
of a drug that is used as eye drop is the β-blocker timolol, which is used in the treatment of 
glaucoma, high intraocular pressure.  The highest concentration of timolol is in the eye, and 
that is where the predominant effects are.  Major systemic effects are not observed after 
timolol is applied topically to the eye. 
Drugs can also be administered to the eye in the form of an ointment.  A small amount of 
ointment is put along the inside of the lower eyelid.  Then, blinking will spread the ointment 
over the cornea, and the drug will be absorbed.  This provides a more prolonged contact time 
with the cornea, and more prolonged absorption.  With ointments, the application to the eye is 
less often than with drops. 
1.9.4 Vaginal 
Suppository-shaped medications are available for vaginal administration. These are known as 
pessaries, and are designed to obtain a local effect.  An example of a drug used in a pessary 
is clotrimazole, an anti-fungal drug for the treatment of vaginal candidiasis (thrush). 
1.10 Pulmonary – Inhalation 
Drugs used for effects on the pulmonary system are often administered by inhalation to give 
the highest concentrations of the drug in the lung.  The human respiratory tract has a 
considerable surface area, which should aid absorption, but most of this is deep in the 
alveolar region of the lung and it is difficult to deliver drugs deep into the lung.  Inhalation is 
not actually a very good way of delivering drugs to the lung, as only about 10% of a drug that 
is inhaled actually goes to the lungs, the rest is swallowed, and may be absorbed from the 
gastrointestinal tract. 
With inhalation, predominant local effects are achieved in pulmonary diseases (e.g. bronchial 
asthma) by having the highest concentration of the drug in the lung.  In asthma, metered-
dose inhalers are used.  These have an inert propellant gas, and require good hand-breath co-
ordination to achieve inhalation, rather than swallowing.  An example of a drug that is used in 
a metered-dose inhaler is salbutamol for the treatment of bronchial asthma.  Another way to 
deliver drugs to the airways is to use a nebulisers.  Nebulisers produce fine droplets in the air 
(aerosol), and are used to deliver large doses of drugs in an emergency.  Thus, in the 
emergency treatment of asthma, large doses of salbutamol can be delivered by a nebuliser. 
Local pulmonary effects can be achieved by using drugs that are poorly absorbed.  For 
example, the glucocorticoid beclomethasone is poorly absorbed from the pulmonary 
epithelium in bronchial asthma.  Thus, it remains in the lung to have an anti-inflammatory 
effect in asthma.  Localised pulmonary effects without major systemic adverse effects can 
also be achieved by inhaling drugs that undergo extensive liver metabolism.  For example, 
after inhalation, the glucocorticoid budesonide has anti-inflammatory effects on the lung.  As 
budesonide is rapidly metabolised by liver this prevents it from having serious systemic 
adverse effects. 
After inhalation, when a drug is deep into the lung, access to the circulation is rapid because 
the lung has a large surface area.  Thus, inhalation can also be used for widespread effects, 
including central effects.  For instance inhalation is used for gaseous and volatile 
anaesthetics, which are rapidly absorbed through the pulmonary epithelium and mucous 
membranes of the respiratory tract, and have their anaesthetic effect within the central 
nervous system.   
Methoxyflurane was introduced as an inhalation anaesthetic, but was withdrawn because of 
toxicity.  Lower less toxic doses of methoxyflurane are analgesic and are used for the 
treatment of acute pain in the emergency situation. The analgesic effect of methoxyflurane is 
mediated by the central nervous system. 
1.11 Intraosseous 
Intraosseous is into the bone marrow.  The bone marrow is highly vascular, which means that 
drugs injected into the bone marrow are rapidly circulated.  The needle injection is through 
the outer bone layer to the soft marrow interior.  The injection is usually done just below 
knee.  Intraosseous is not the first choice for drug administration.  It is usually only done after 
two attempts at inserting a line to do an intravenous infusion have failed.  Examples of when 
intraosseous can be used include, a child 5 years or younger who is unconscious, 
unresponsive and in immediate danger of dying.  Intraosseus is also used when 
cardiopulmonary resuscitation support is required, and this is for patients of all ages, and in 
circulatory shock treatments where there is collapse of the circulation making cannulation 
difficult.  
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9. Drugs and neurotransmitters 
9.1 Introduction 
Every step, in the physiological system for a neurotransmitter, is a possible step at which 
drugs can modify the effects of the neurotransmitter.  Thus, most neurotransmitters are 
synthesised, stored, released, and have receptor mediated effects involving cell signaling, 
before the neurotransmitter is inactivated by being broken down (metabolism) or be transport 
back into the nerve.  Thus, synthesis, release, receptors, cell signaling, and inactivation are all 
sites at which drugs can modify the actions of neurotransmitters.  In theory, drugs can 
increase or decrease any of the steps.  In this chapter, one or two important examples of drugs 
acting at each of these steps is considered. 
 
9.2 Synthesis 
The example of a drug that can increase the synthesis of a neurotransmitter is L-DOPA.  L-
DOPA is used to increase the levels of dopamine, a neurotransmitter in the brain, in 
Parkinson’s disease.  Normal ageing is associated with a loss of dopaminergic neurones 
(nerves that contain dopamine) in the central nervous system.  However, there is a greater 
loss of dopaminergic neurones in Parkinson’s disease, which was first described by 
Parkinson.  Thus, a 70-80% loss of dopaminergic neurones is associated with Parkinson’s 
disease.  
 
The clinical syndrome that distinguishes Parkinson’s disease consists of 4 parts.  Firstly, there 
is bradykinesia (which is a slowness/poverty of movement).  Secondly, there is muscular 
rigidity, which makes starting a movement difficult.  There may also be resting tremors but 
these usually stop during voluntary movement.  Lastly, there is impairment of balance, with 
disturbances of gait (movement of limbs) and the subjects with Parkinson’s disease lean 
forward.  Impairment of balance leads to an increased risk of falling. 
The main treatment of Parkinson’s disease is to enhance the dopaminergic system.  Probably, 
the most obvious way to enhance the dopaminergic system is to give dopamine.  However, 
dopamine is not active after oral administration as it is metabolised by 2 enzymes (monamine 
oxidase and catechol-O-methyl transferase), which are found in the gut.  To avoid intestinal 
metabolism, dopamine can be administered intravenously.  But, after intravenous 
administration, dopamine does not cross the blood brain barrier to have central effects.  Thus, 
we cannot use dopamine in Parkinson’s disease. 
A very important way to enhance the dopaminergic system is to increase the synthesis of 
dopamine.  L-DOPA is the precursor of dopamine.  It is absorbed from the gut on the 
transporter system for the aromatic amino acids.  L-DOPA also gains entry into central 
nervous system, with transport across the blood brain barrier also being mediated by the 
transporter for the aromatic amino acids.  Once in dopaminergic neurones, L-DOPA is 
converted to dopamine.  When the dopaminergic neurones are activated, the dopamine is 
released and overcomes the symptoms of Parkinson’s disease. 
9.3 Release 
The next level at which the actions of a neurotransmitter can be modified is at the level of 
release.  Theoretically, drugs can be used to inhibit or increase the release of 
neurotransmitters.  A drug that inhibits the release of neurotransmitters is lignocaine.  
Lignocaine is a Na
+
 channel blocker.  The conduction of impulses along nerves requires the 
opening and closing of sodium channels.  Lignocaine is commonly used as a local 
anaesthetic, as application to afferent/sensory nerves stops the conduction of impulses that 
translate into the sensation of pain in the brain.  Thus, prior to minor surgery, lignocaine can 
be used locally to dull pain. 
 
A drug that increases the release of a neurotransmitter is amantadine.  Thus, a second 
approach to enhancing dopaminergic neurotransmission in Parkinson’s disease, is to promote 
the release of endogenous dopamine.  Amantadine increases the release of dopamine from the 
dopaminergic nerves in the brain.  Amantadine is not very effective alone.  It is only used 
alone in the early stages of Parkinson’s disease where there are still sufficient stores of 
endogenous dopamine to allow amantadine to release dopamine. 
9.4 Receptors 
Drugs can act at receptor to mimic the effect of the endogenous substance, and this is known 
as agonism.  Conversely, drugs can act at receptors to block the effects of endogenous 
substances, and this is antagonism.  The sites of actions of drugs can be limited, if the drug 
shows selectivity for a receptor.  Examples from the sympathetic nervous system are to be 
used to explain this.  Noradrenaline (released from the sympathetic nervous system) and 
adrenaline (released from the adrenal medulla) stimulate all the peripheral adrenoceptors to 
have widespread effects.  They can act on the β2-adrenoceptors in the lung to cause 
bronchodilation, and they can act on the β1-adrenoceptors of the heart to increase heart rate 
and force.  The selective β2-adrenoceptor agonist salbutamol has no effect at α-
adrenoceptors, and is selective for β2- over β1-adrenoceptors.  Salbutamol is the standard 
selective β2-adrenoceptor agonist used to cause bronchodilation in an asthma attack. The β1-
selective adrenoceptor antagonist atenolol is selective, not specific, for β1-adrenoceptors, and 
have some effects at β2-adrenoceptors.  The selective β1-blockers are used in the treatment of 
hypertension. 
 
9.5 Cell signaling 
There are not a lot of drugs used for their ability to interfere with the cell signaling of 
neurotransmitters, probably because it is usually easier to target the receptor for the 
neurotransmitter. Benzodiazepines (e.g. diazepam) are the main drugs used to treat anxiety 
and insomnia, and to cause sedation.  The benzodiazepines potentiate the effects on an 
inhibitory neurotransmitter in the central nervous system by modifying its cell signaling.  
This inhibitory neurotransmitter is gamma (γ)-aminobutyric acid (GABA).  There are cell 
surface receptors for GABA and there are two main types GABAA and GABAB.  The 
GABAA receptor is the one the benzodiazepines interact with.  The GABAA receptor has 5 
subunits that form a Cl- channel (Figure 9.1).  Benzodiazepines bind to a distinct binding site, 
the benzodiazepine binding site on the GABAA receptor to potentiate the effect of GABA, 
which is to open the chloride channel, and the more chloride that goes through the channel, 
the bigger the inhibitory effect.  Benzodiazepines have no effect alone, and are only effective 
when GABA is present. 
  
Figure 9.1 Benzodiazepine binding site, GABAA receptor and chloride channel (Copyright 
QUT, Sheila Doggrell) 
9.6 Inactivation 
Neurotransmitter can be inactivated by metabolism or by being transported back into the 
nerve to be used.  Drugs that modify the actions of the neurotransmitter at the level of 
metabolism usually inhibit it to increase the level of the neurotransmitter.  Similarly drugs 
that modify at the level of the transporter usually inhibit, and the level of the 
neurotransmitter.  
 
9.6.1 Inactivation by metabolism 
A drug used to inhibit the metabolism of a neurotransmitter is entacapone, which is used to 
increase the levels of dopamine in Parkinson’s disease.  Parkinson’s disease is a progressive 
disease, which means there is a progressive loss of dopaminergic neurones.  The 
dopaminergic neurons are needed to convert the L-DOPA to dopamine.  Thus, with a 
decreasing number of dopaminergic neurones present, there is decreasing ability of 
dopaminergic neurones to convert L-DOPA to dopamine.  Catechol-O-methyl-transferase 
(COMT) is one of the enzymes involved in the metabolism of dopamine. In the periphery, 
catechol-O-methyl-transferase also metabolises L-DOPA, and this metabolism leads to 
inactivation of the L-DOPA.  Entacapone is an inhibitor of catechol-O-methyl-transferase.  In 
the periphery, the ability of entacapone to inhibit the inactivation of L-DOPA leads to more 
L-DOPA being available to be transported into the central nervous system.  In the central 
nervous system, entacapone lead to increased levels of dopamine by preventing its 
metabolism by entacapone.  
  
9.6.2 Inactivation by transport back into the nerve 
An example of a drug that inhibits the inactivation of a neurotransmitter back into a nerve is 
fluoxetine (Prozac).  Fluoxetine inhibits the inactivation of the neurotransmitter 5-
hydroxytryptamine (5-HT), which is useful in the treatment of major depression.  Major 
depression is depression out of proportion with the cause of the depression.  Major depression 
is classically characterized by feelings of intense sadness and despair, mental slowing and 
loss of concentration, pessimistic worry, lack of pleasure, self-deprecation, and agitation or 
hostility.  Major depression is characterised by physical changes, such as insomnia or 
hypersomnia (sleeping too much), altered eating patterns, decreased energy and libido, and 
disruptions of normal circadian rhythms (e.g. hormonal secretion times are altered). 
On activation of the tryptaminergic nerve terminal, 5-HT is released and stimulates 5-HT 
receptors on the postjunctional membrane to have an effect.  5-Hydroxytryptamine (is 
inactivated by transport back into the neurone on the serotonin transporter (SERT), and this 
leads to the termination of action of 5-HT.  The short term effect of fluoxetine (Prozac) is to 
selectively inhibit the SERT transporter, which inhibits the inactivation of 5-HT.  
Consequently, there are increased levels of 5-HT in the synapse, which leads to an increased 
stimulation of receptor, and an increased effect.  Fluoxetine is selective for the SERT 
transporter, and has little effect on the transport of noradrenaline.  Fluoxetine is one example 
of a group of drugs known as the selective serotonin reuptake inhibitors (SSRIs). 
 
